IN8bio director granted options for 22,000 shares

IN8BIO, INC. director Corinne Epperly received a grant of stock options covering 22,000 shares of Common Stock.

Rhea-AI Filing Summary

IN8BIO, INC. director Corinne Epperly received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036, and represent a compensation-related award rather than an open-market trade.

One twelfth of the options vest in equal monthly installments starting on June 9, 2026, with full vesting no later than the company’s next annual meeting of stockholders, as long as she continues providing service through each vesting date.

Insider Trade Summary

Grant/Award: 22,000 shares

Grant/Award 1 txn

Insider Epperly Corinne

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,000 contracts (Direct)

Footnotes (1)

1. F1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

Options granted: 22,000 shares Exercise price: $1.58 per share Expiration date: May 9, 2036 +2 more

5 metrics

Options granted 22,000 shares Stock option grant to director on May 9, 2026

Exercise price $1.58 per share Stock option exercise price for 22,000-share grant

Expiration date May 9, 2036 Option term for director grant

Vesting start June 9, 2026 Monthly vesting of one twelfth of options begins

Post-grant derivative holdings 22,000 options Total options held following the reported transaction

Key Terms

Stock Option (right to buy), Common Stock, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"fully vested on the date of the Company's next annual meeting of stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IN8BIO (INAB) report for Corinne Epperly?

IN8BIO reported that director Corinne Epperly received a grant of stock options for 22,000 shares of Common Stock. The options are a compensation-related award, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many IN8BIO (INAB) shares are covered by Corinne Epperly’s new options?

The option grant covers 22,000 underlying shares of IN8BIO Common Stock. These options give the director the right to buy that number of shares at the specified exercise price once they vest, subject to the vesting schedule and continued service conditions.

What is the exercise price and expiration date of Corinne Epperly’s IN8BIO options?

The options have an exercise price of $1.58 per share and expire on May 9, 2036. This means she can choose to buy shares at $1.58 any time after vesting, up until the stated expiration date, if other plan conditions are satisfied.

How do Corinne Epperly’s IN8BIO (INAB) options vest over time?

One twelfth of the 22,000-share option vests in equal monthly installments beginning June 9, 2026. However, the grant will be fully vested by the date of IN8BIO’s next annual meeting of stockholders, provided she continues to provide service through each vesting date.

Is Corinne Epperly’s Form 4 transaction a buy or sell of IN8BIO stock?

The Form 4 shows an acquisition of derivative securities through a grant of stock options, coded as a compensation award. It is not an open-market buy or sell of existing IN8BIO shares but a right to purchase shares in the future at $1.58 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Corinne

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVENUE, SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	05/09/2026		A		22,000		(1)	05/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)